DarioHealth financials
$6.62−1.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.4M | $27.0M | $20.4M | $27.7M | $20.5M | $7.6M | $7.6M | $7.4M | $5.2M | $2.8M |
| Gross profit | $12.7M | $13.3M | $6.0M | $9.7M | $4.0M | $2.5M | $2.6M | $1.8M | $1.3M | -$830.0K |
| Gross margin | 56.6% | 49.1% | 29.4% | 34.9% | 19.3% | 33.2% | 34.4% | 23.9% | 25.4% | −29.6% |
| Operating income | -$36.7M | -$57.7M | -$56.2M | -$56.8M | -$76.5M | -$29.9M | -$17.7M | -$17.7M | -$14.4M | -$11.1M |
| Net income | -$40.3M | -$30.1M | -$54.9M | -$58.0M | -$67.5M | -$33.1M | -$20.9M | -$18.3M | -$16.0M | -$11.6M |
| Net margin | −180.3% | −111.3% | −269.6% | −209.6% | −329.2% | −436.9% | −276.4% | −247.4% | −309.4% | −414.1% |
| Diluted EPS | $-10.12 | $-12.27 | $-38.60 | $-50.80 | $-81.40 | $-111.02 | $-184.40 | $-312.60 | $-664.00 | $-892.00 |
| EBITDA | -$33.5M | -$50.3M | -$51.2M | -$52.1M | -$72.0M | -$29.7M | -$17.5M | -$17.5M | -$14.2M | -$10.7M |
| Operating cash flow | -$25.9M | -$38.6M | -$30.4M | -$47.8M | -$50.4M | -$17.7M | -$15.7M | -$11.5M | -$10.6M | -$8.4M |
| Free cash flow | -$26.1M | -$38.7M | -$31.0M | -$48.3M | -$50.7M | -$17.9M | -$15.8M | -$11.5M | -$10.8M | -$9.2M |
| Diluted shares | 4.0M | 2.5M | 1.4M | 1.2M | 0.8M | 0.3M | 0.1M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $21.8M | $27.8M | $36.8M | $49.4M | $35.8M | $28.6M |
| Short-term investments | $4.2M | $697.0K | $0.00 | $0.00 | — | — |
| Total debt | $30.7M | $28.9M | $28.5M | $26.9M | $0.00 | $0.00 |
| Total assets | $110.1M | $118.9M | $96.4M | $119.2M | $100.8M | $35.4M |
| Total liabilities | $42.2M | $46.9M | $38.2M | $39.2M | $15.2M | $7.3M |
| Shareholders' equity | $67.9M | $72.0M | $58.1M | $80.0M | $85.5M | $28.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology